Automated instrumentation for production of T-cell receptor peptide libraries

US11396718B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11396718-B2
Application numberUS-202217690641-A
CountryUS
Kind codeB2
Filing dateMar 9, 2022
Priority dateApr 24, 2018
Publication dateJul 26, 2022
Grant dateJul 26, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present disclosure provides instrumentation and automated methods for creating cell surface display libraries, where the cells of the library display engineered peptides on their cell surfaces for identification of antigens that bind to T-cell receptors. The engineered peptides may be putative antigens or binding regions of the T-cell receptors.

First claim

Opening claim text (preview).

We claim: 1. An automated method of creating a cell library co-expressing engineered proteins and MHC molecules, the method comprising: processing a population of cells using an instrument for multiplexed nuclease-directed genome editing using introduced nucleic acids and a nuclease, wherein the introduced nucleic acids comprise nucleic acids that encode engineered proteins and MHC molecules configured to be displayed on surfaces of the cells, the engineered proteins comprising unique polypeptides linked to immobilization peptides for immobilization on the surfaces of the cells; incubating the processed cells to facilitate nucleic acid editing in the cells, wherein the edited cells co-express the engineered proteins and MHC molecules in the cells; and allowing the cells to display the engineered proteins and the MHC molecules on the surfaces of the cells. 2. The method of claim 1 , wherein the immobilization peptides comprise a first binding motif that selectively binds to a second binding motif present on the surfaces of the cells. 3. The method of claim 2 , wherein the first binding motif comprises avidin, streptavidin, or neutravidin. 4. The method of claim 2 , wherein the second binding motif comprises biotin. 5. The method of claim 1 , wherein the immobilization peptides comprise a transmembrane polypeptide, a polypeptide membrane anchor, a GPI-linked polypeptide, or a natural surface polypeptide. 6. The method of claim 1 , wherein the immobilization peptides are linked to a C-terminus or an N-terminus of the unique polypeptides. 7. The method of claim 1 , wherein the unique polypeptides comprise putative T-cell receptor (TCR) antigens. 8. The method of claim 1 , wherein the unique polypeptides comprise predicted T-cell receptor (TCR) binding regions. 9. An automated method of creating a cell library co-expressing engineered proteins and MHC molecules, the method comprising: processing a population of cells using an instrument for multiplexed nuclease-directed genome editing using introduced nucleic acids and a nuclease, wherein the introduced nucleic acids comprise nucleic acids that encode engineered proteins and MHC molecules configured to be displayed on surfaces of the cells, the engineered proteins comprising unique polypeptides linked to immobilization peptides for immobilization on the surfaces of the cells, the unique polypeptides comprising putative T-cell receptor (TCR) antigens or predicted TCR binding regions; incubating the processed cells to facilitate nucleic acid editing in the cells, wherein the edited cells co-express the engineered proteins and MHC molecules in the cells; and allowing the cells to display the engineered proteins and the MHC molecules on the surfaces of the cells. 10. The method of claim 9 , wherein the immobilization peptides comprise a first binding motif that selectively binds to a second binding motif present on the surfaces of the cells. 11. The method of claim 10 , wherein the first binding motif comprises avidin, streptavidin, or neutravidin. 12. The method of claim 10 , wherein the second binding motif comprises biotin. 13. The method of claim 9 , wherein the immobilization peptides comprise a transmembrane polypeptide, a polypeptide membrane anchor, a GPI-linked polypeptide, or a natural surface polypeptide. 14. The method of claim 9 , wherein the immobilization peptides are linked to a C-terminus or an N-terminus of the unique polypeptides. 15. An automated method of creating a cell library expressing engineered proteins on surfaces of the cells, the method comprising: processing a population of cells using an instrument for multiplexed nuclease-directed genome editing using introduced nucleic acids and a nuclease, wherein the introduced nucleic acids comprise nucleic acids that encode engineered proteins to be displayed on surfaces of the cells, the engineered proteins comprising unique polypeptides linked to immobilization peptides for immobilization on the surfaces of the cells; incubating the processed cells to facilitate nucleic acid editing in the cells, wherein the edited cells express the engineered proteins in the cells; and allowing the cells to display the engineered proteins on the surfaces of the cells. 16. The method of claim 15 , wherein the immobilization peptides comprise a first binding motif that selectively binds to a second binding motif present on the surfaces of the cells. 17. The method of claim 16 , wherein the first binding motif comprises avidin, streptavidin, or neutravidin. 18. The method of claim 16 , wherein the second binding motif comprises biotin. 19. The method of claim 15 , wherein the immobilization peptides comprise a transmembrane polypeptide, a polypeptide membrane anchor, a GPI-linked polypeptide, or a natural surface polypeptide. 20. The method of claim 15 , wherein the unique polypeptides comprise putative T-cell receptor (TCR) antigens or predicted TCR binding regions.

Assignees

Inventors

Classifications

  • MHC-molecules, e.g. HLA-molecules · CPC title

  • Ribonucleases {[RNase]; Deoxyribonucleases [DNase]} · CPC title

  • Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors · CPC title

  • Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display · CPC title

  • for yeasts · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11396718B2 cover?
The present disclosure provides instrumentation and automated methods for creating cell surface display libraries, where the cells of the library display engineered peptides on their cell surfaces for identification of antigens that bind to T-cell receptors. The engineered peptides may be putative antigens or binding regions of the T-cell receptors.
Who is the assignee on this patent?
Inscripta Inc
What technology area does this patent fall under?
Primary CPC classification C07K14/70539. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jul 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).